



Attorney D. [redacted] No.: 082375-000000US
Client Reference No.: M3-104PCT-US

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Suzuki et al.

Application No.: 10/049,336

Filed: February 4, 2002

For: METHOD FOR MEASURING
KINASE ACTIVITY OF CYCLIN/CDK
COMPLEX

Examiner: Unassigned

Art Unit: Unassigned

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. The references cited in this statement were also cited in the International Search Report of the international phase of the present application. Copies of the references are not being provided as it is assumed that they have been provided to the USPTO already from WIPO. If the Examiner does not have copies she is requested to contact the undersigned. Copies of the International Search Report and International Preliminary Examination Report are included with this statement as a concise explanation of the relevance of the references, which are in Japanese. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or

are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known


Application Number	10/049,336
Filing Date	February 4, 2002
First Named Inventor	Suzuki
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	082375-000000U

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Date Considered

PA 3253731 v1



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/049,336
Filing Date	February 4, 2002
First Named Inventor	Suzuki
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	082375-000000US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	INOMATA et al., "Keratinocyte no Zoushoku, Ganka no Target; Cycline cdk Fukugoutai," <u>Nishinihon J. Dermatology</u> , 57(4):687-695 (1995).	
	AB	OGAWA, S., "Saibou shuuki yokusei inshi," <u>Hematology and Oncology</u> , 32(2):123-128 (1996).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3253731 v1